Business briefs: GlaxoSmithKline, Burson-Marsteller

Share this article:

GlaxoSmithKline's Wednesday earnings announcement opened with CEO Andrew Witty saying the company was entering the year with “the potential to launch 15 new drugs” between now and 2016. Witty also said in a statement that 2013 will be the basis for “what should be a series of growth years for GSK.” The company's fourth quarter closed with $11 billion in sales, flat against the same period last year. GSK saw 2012 sales slide 1% for the year, to $41 billion. Pharmaceutical and vaccine sales slid 2% during the quarter and 2% during the year. Consumer sales were flat for the quarter and for the year, although GSK said US consumer sales rose 2% while Europe's were flat. The company attributed this performance partly to the economy,  but also to what it called “the drag from Alli,” the over-the-counter weight-loss drug that it hasn't been able to cleave from its portfolio.

PR firm Burson-Marsteller made a pair of appointments, announcing that the ex-Cord Blood Registry chief marketing officer David Zitlow will chair its US healthcare practice while Lisa Davidson, who has led the New York healthcare team since 2009, becomes US deputy chair. Zitlow's background includes a stint as EVP of the healthcare practice for GolinHarris. Davidson previously headed up the healthcare practice at Porter Novelli, where she was a partner.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.